Personal Account
Personal Account
A running list of upcoming and recently priced US IPOs, updated weekly. Dates, price ranges and deal sizes change frequently ahead of pricing — treat the table below as a snapshot as of July 31, 2026, and confirm details before making any decision.
Upcoming and Recent IPOs
| Company | Ticker | Price Range | Est. Deal Size | Expected Date |
|---|---|---|---|---|
| Apnimed | APMD | $16.00 | $192.0M | Priced 7/31/2026 |
| Churchill Capital XIII (SPAC) | XIIIU | $10.00 | $360.0M | Priced 7/31/2026 |
| East West Ave Acquisition Corp. (SPAC) | EWAVU | $10.00 | $100.0M | Priced 7/31/2026 |
| BOA Acquisition Corp. II (SPAC) | THEOU | $10.00 | $125.0M | 8/4/2026 |
| Attovia Therapeutics | ATTO | $15.00–$17.00 | $200.0M | 8/5/2026 |
| Braveheart Bio | BRVE | $15.00–$17.00 | $300.0M | 8/6/2026 |
| Vogenx | VOGX | $11.00–$13.00 | $75.0M | 8/6/2026 |
| Web3Labs Global | MDAT | $4.00–$5.00 | $28.1M | Week of 8/7/2026 |
| BW Industrial Holdings | BWGC | $6.00–$7.00 | $17.1M | Week of 8/10/2026 |
| MetaOptics (uplisting) | MOT | $5.00–$7.00 | $18.0M | Week of 8/10/2026 |
| Riku Dining Group | RIKU | $4.00–$6.00 | $25.0M | Week of 8/10/2026 |
What to Watch
- A biotech IPO wave. Attovia Therapeutics, Braveheart Bio and Vogenx are pricing within days of each other, together targeting over $500 million raised. Braveheart is developing an oral treatment for hypertrophic cardiomyopathy; Attovia (spun out of Alamar Biosciences) is testing a therapy for chronic itch conditions targeting the IL-31 pathway. Multiple biotechs pricing in the same window is typically a sign that bankers see a receptive window for the sector — it can close quickly if early deals price or trade poorly.
- Three SPACs in the mix. Churchill Capital XIII, East West Ave Acquisition Corp. and BOA Acquisition Corp. II are blank-check companies (SPACs) — they raise money first and identify an acquisition target later. A SPAC IPO is a bet on the sponsor's deal-making track record, not on a specific operating business, which makes it a fundamentally different risk profile from a standard operating-company IPO.
Fact vs. estimate: tickers, price ranges and deal sizes reflect terms as filed/marketed at time of writing and can change before pricing. Expected dates for deals not yet priced are estimates.
Why It Matters for Pre-IPO and Tokenized Equity Investors
Most names on a public IPO calendar are companies that were pre-IPO investments not long ago. Watching which sectors are actively pricing (biotech this week, SPACs persistently active through 2026) is a useful read on where public-market appetite currently sits — and by extension, which categories of still-private companies may find a receptive IPO window if they choose to list next.
This material is for informational purposes only and does not constitute individual investment advice.